ARA Becomes the Latest Clinical Research Organization (CRO) to Join the iMedNet Partner Program
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is pleased to announce that Advance Research Associates (ARA), a CRO dedicated to delivering high quality data management and biostatistical services, has selected iMedNet EDC as its preferred eClinical solution.
MedNet Solutions
, a global life sciences technology company specializing in clinical study management systems, is pleased to announce that
Advance Research Associates
(ARA), a CRO dedicated to delivering high quality data management and biostatistical services, has selected
iMedNet EDC
as its preferred eClinical solution. As the latest member of MedNet’s growing iMedNet Partner Program, ARA will benefit from a wide range of wrap-around services designed to help ARA maximize their iMedNet EDC return on investment.
“ARA is excited to offer the iMedNet solution,” remarked Michelle Stoddard, Senior Director of Operations at ARA. “Their software as a service (SaaS) model combined with the wide ranging functionalities offered within iMedNet make this solution an ideal combination of configurability and value for a wide range of clinical study types and durations.”
“MedNet’s comprehensive, well-documented Quality Management System (QMS) gives us the security of knowing that client deliverables are the outcome of processes that meet or exceed regulatory and 21 CFR Part 11 compliance requirements,” noted Heather Zollinger, Senior Quality Systems Manager at ARA. “I am very excited about the new opportunities for both ARA and MedNet that result from this partnership.”
“MedNet is pleased to partner with ARA, a CRO known in the industry for their deep industry experience, highly experienced staff and their collaborative work approach with customers,” stated Brian Sweeney, VP of Business Development at MedNet. “We’re looking forward to a long, mutually beneficial relationship assisting ARA and their customers in meeting their clinical research objectives.”
Please contact MedNet Solutions for more information on iMedNet EDC or the iMedNet Partner Program, and ARA for additional details on their biostatistics and data management capabilities.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
